Multidrug-resistant tuberculosis in the United Kingdom and Lithuania

International Journal of Tuberculosis and Lung Disease

Volumn 18, Issue 6, 2014, Pages

  Gonzalo, X ^a   Hutchison, D C S ^a   Drobniewski, F A ^a   Pimkina, E ^b   Davidaviciene, E ^b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b VILNIUS UNIVERSITY   (Lithuania)

Author keywords

Aminoglycoside resistance; Drug susceptibility testing; MDR TB; XDR TB

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; CAPREOMYCIN; ETHAMBUTOL; KANAMYCIN; MOXIFLOXACIN; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TUBERCULOSTATIC AGENT;

AFRICA; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; ASIA; CONTROLLED STUDY; ETHNIC DIFFERENCE; HUMAN; LITHUANIA; MAJOR CLINICAL STUDY; MICROBIOLOGICAL EXAMINATION; MONOTHERAPY; MULTIDRUG RESISTANT TUBERCULOSIS; PRIORITY JOURNAL; UNITED KINGDOM; EPIDEMIOLOGY; ETHNOLOGY; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIGRANT; MIGRATION; MULTIDRUG RESISTANCE; PREVALENCE; REGISTER; RETROSPECTIVE STUDY; RISK FACTOR; TIME; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANTITUBERCULAR AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EMIGRANTS AND IMMIGRANTS; EMIGRATION AND IMMIGRATION; GREAT BRITAIN; HUMANS; LITHUANIA; MICROBIAL SENSITIVITY TESTS; PREVALENCE; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84901289498     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.13.0342     Document Type: Article

References (10)

1. Mitchell S L, Seoudi N, Hutchison D C S, Drobniewski F A. Multidrug-resistant tuberculosis: resistance rates to first and reserve anti-tuberculosis drugs in the UK in 2008/9 and the role of rapid molecular tests for drug resistance. Thorax 2011; 66: 630-631.
2. Marks J. A 'stepped pH' technique for the estimation of pyrazinamide sensitivity. Tubercle 1964; 45: 47-50.
3. Krüüner A, Yates M D, Drobniewski F A. Evaluation of MGIT 960-based antimicrobial testing and determination of critical concentrations of first- and second-line antimicrobial drugs with drug-resistant clinical strains of Mycobacterium tuberculosis. J Clin Microbiol 2006; 44: 811-818.
4. Health Protection Agency. Tuberculosis in the UK: annual report on tuberculosis surveillance in the UK, 2012. London, UK: HPA, 2012.
5. Abubakar I, Moore J, Drobniewski F, et al. Extensively drug-resistant tuberculosis in the UK: 1995 to 2007. Thorax 2009; 64: 512-515.
6. Zignol M, van Gemert W, Falzon D, et al. Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007-2010. Bull World Health Organ 2012; 90: 111-119D.
7. Krüüner A, Jureen P, Levina K, Ghebremichael S, Hoffner S. Discordant resistance to kanamycin and amikacin in drug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003; 47: 2971-2973. (Pubitemid 37040278)
8. Balabanova Y, Radiulyte B, Davidaviciene E, et al. Survival of drug resistant tuberculosis patients in Lithuania: retrospective national cohort study. 2011 BMJ Open; 1: e000351.
9. Balabanova Y, Ruddy M, Hubb J, et al. Multidrug-resistant tuberculosis in Russia: clinical characteristics, analysis of second-line drug resistance and development of standardized therapy. Eur J Clin Microbiol Infect Dis 2005; 24: 136-139. (Pubitemid 40487382)
10. Kruijshaar M E, Abubakar I, Dedicoat M, et al. Evidence for a problem: continued rise in tuberculosis case numbers in urban areas outside London. Thorax 2012; 67: 275-277.